Xingzhong Hu

Xingzhong Hu

Auto-generated profile, based on publicly available information

Xingzhong Hu

Department of Clinical Laboratory Medicine, Wenzhou Central Hospital, Dingli Clinical School of Wenzhou Medical University, Wenzhou 325000, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
SSSuyu Sun
Suyu Sun
XCXuejiao Cai
Xuejiao Cai
HWHuaguo Wang
Huaguo Wang
GHGuiqing He
Guiqing He
YLYin Lin
Yin Lin
XHXingzhong Hu
Xingzhong Hu

1 August 2021 in Endocrine Practice
Verified
Journal Article
Closed access
MCMochuan Chen
Mochuan Chen
BZBing Zhu
Bing Zhu
DCDong Chen
Dong Chen
XHXingzhong Hu
Xingzhong Hu
XXXueqin Xu
Xueqin Xu
SQShen Qu
Shen Qu

2 November 2018 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
PDF file
YPYong Pan
Yong Pan
WBWenjing Bai
Wenjing Bai
JCJiangnan Chen
Jiangnan Chen
YMYijian Mao
Yijian Mao
XQXiaohong Qian
Xiaohong Qian
XHXingzhong Hu
Xingzhong Hu

1 July 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
SSSuyu Sun
Suyu Sun
WKWanzhong Kong
Wanzhong Kong
XCXiaoya Cui
Xiaoya Cui
YLYin Lin
Yin Lin
BLBibi Lu
Bibi Lu
XHXingzhong Hu
Xingzhong Hu

28 November 2024 in Heliyon
Verified
Journal Article
Open access
YLYing Lin
Ying Lin
MCMing Chen
Ming Chen
XZXuelian Zhu
Xuelian Zhu
XCXiaoya Cui
Xiaoya Cui
SSSuyu Sun
Suyu Sun
XHXingzhong Hu
Xingzhong Hu
The relationship between tumour necrosis factor (TNF) levels and disease progression is well-established. However, the impact of changes in the level of TNF hydrolase (A-disintegrin and metalloenzyme 17; ADAM17) in HIV patients remains to be fully elucidated. Between March 1 and December 31, 2017, data were collected from 64 HIV-positive individuals in Wenzhou. Based on their history of antiviral treatment at the time of enrollment, these patients were categorized into two cohorts: an antiviral-treated group and an untreated HIV group. Then, the serum ADAM17 levels of each group were measured and analysed. In comparison to the antiviral-treated group and the control group, the untreated HIV group exhibited a significantly elevated serum ADAM17 level (p < 0.001). A significant negative correlation was observed between serum ADAM17 levels and CD4+ T cell counts in the untreated HIV group (r = −0.486, p = 0.001). ROC curve analysis revealed that the pre-treatment serum ADAM17 level in the untreated HIV group had moderate diagnostic accuracy for the AIDS stage (area under the curve: 0.703, p = 0.028). Additionally, serum ADAM17 levels were positively correlated with ADAM17 expression on the surface of leukocytes (r = 0.367, p = 0.018). Serum ADAM17 levels are significantly elevated in HIV patients and are correlated with disease progression and immune reconstitution.